Androgen receptor cytosine-adenine-guanine repeat polymorphisms modulate EGFR signaling in epithelial ovarian carcinomas

Gynecologic Oncology

Volumn 109, Issue 2, 2008, Pages 220-225

  Li, Andrew J ^a   Scoles, Daniel R ^a   Armstrong, Klara U M ^a   Karlan, Beth Y ^a  

^a CEDARS SINAI MEDICAL CENTER   (United States)

Author keywords

Androgen receptor; EGFR; Ovarian cancer

Indexed keywords

ADENINE; ANDROGEN RECEPTOR; CYTOSINE; EPIDERMAL GROWTH FACTOR RECEPTOR; GUANINE; LUCIFERASE; MITOGEN ACTIVATED PROTEIN KINASE;

ALLELE; ANALYSIS OF VARIANCE; ARTICLE; CANCER CELL CULTURE; CANCER SURVIVAL; CELL PROLIFERATION; CORRELATION ANALYSIS; ENZYME PHOSPHORYLATION; HUMAN; HUMAN CELL; NITROBLUE TETRAZOLIUM TEST; NUCLEOTIDE REPEAT; OVARY CARCINOMA; PHENOTYPE; PLASMID; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; STUDENT T TEST; WESTERN BLOTTING;

ADENINE; ALLELES; CARCINOMA; CELL LINE, TUMOR; CELL PROLIFERATION; CYTOSINE; FEMALE; GUANINE; HUMANS; MITOGEN-ACTIVATED PROTEIN KINASES; OVARIAN NEOPLASMS; PHOSPHORYLATION; POLYMORPHISM, GENETIC; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTORS, ANDROGEN; SIGNAL TRANSDUCTION; TRANS-ACTIVATION (GENETICS); TRANSFECTION; TRINUCLEOTIDE REPEATS;

EID: 43049123055     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2008.02.010     Document Type: Article

References (24)

1. Risch H.A. Hormonal etiology of epithelial ovarian cancer, with a hypothesis concerning the role of androgens and progesterone. J Natl Cancer Inst 90 (1998) 1774-1786
2. Chadha S., et al. An immunohistochemical evaluation of androgen and progesterone receptors in ovarian tumors. Hum Pathol 24 (1993) 90-95
3. Cardillo M.R., Petrangeli E., Aliotta N., et al. Androgen receptors in ovarian tumors: correlation with oestrogen and progesterone receptors in an immunohistochemical and semiquantitative image analysis study. J Exp Clin Cancer Res 17 (1998) 231-237
4. Chamberlain N.L., et al. The length and location of CAG trinucleotide repeats in the androgen receptor N-terminal domain affect transactivation function. Nucleic Acids Res 22 (1994) 3181-3186
5. Tut T.G., et al. Long polyglutamine tracts in the androgen receptor are associated with reduced trans-activation, impaired sperm production, and male infertility. J Clin Endo Metabol 82 (1997) 3777-3782
6. Spurdle A, Webb P.M., Chen X., et al. Androgen receptor exon 1 CAG repeat length and risk of ovarian cancer. Int J Cancer 87 (2000) 637-643
7. Li A.J., et al. Short androgen receptor allele length is a poor prognostic factor in epithelial ovarian carcinoma. Clin Cancer Res 9 (2003) 3667-3673
8. Cross M, et al. Growth factors in development, transformation, and tumorigenesis. Cell 64 (1991) 271-280
9. Strawn LM, et al. Tyrosine kinases in disease: overview of kinase inhibitors as therapeutic agents and current drugs in clinical trials. Ex Opin Invest Drugs 7 (1998) 553-573
10. Alper O, Bergmann-Leitner E.S., Bennett T.A., et al. Epidermal growth factor receptor signaling and the invasive phenotype of ovarian carcinoma cells. J Natl Cancer Inst 93 (2001) 1375-1384
11. Liu XH, et al. Androgens regulate proliferation of human prostate cancer cells in culture by increasing transforming growth factor-alpha and epidermal growth factor/TGF-alpha receptor. J Clin Endocrinol Metab 77 (1993) 1472-1478
12. Bonaccorsi L, Muratori M., Carloni V., et al. The androgen receptor associates with the epidermal growth factor receptor in androgen-sensitive prostate cancer cells. Steroids 69 (2004) 549-552
13. Scoles DR, Pavelka J.C., Cass I., et al. Characterization of CSOC 882, a novel immortalized ovarian cancer cell line expressing EGFR, HER2, and activated AKT. Gynecol Oncol 104 (2007) 120-128
14. Rasband W.S. ImageJ, National Institutes of Health (2004), Bethesda, Maryland, USA. http://rsb.info.nih.gov/ij/ http://rsb.info.nih.gov/ij/
15. Poullet P., et al. Use of the yeast two-hybrid system to evaluate ras interactions with neurofibromin GTPase-activating proteins. Methods Enzymol 255 (1995) 488-497
16. Buchanan G., Yang M., Cheong A., et al. Structural and functional consequences of glutamine tract variation in the androgen receptor. Hum Mol Genet 13 (2004) 1677-1692
17. Ilekis JV, Connor J.P., Prins G.S., et al. Expression of epidermal growth factor and androgen receptors in ovarian cancer. Gynecol Oncol 66 (1997) 250-254
18. Tannock I.F., Osoba D., Stockler M.R., et al. Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points. J Clin Oncol 14 (1996) 1756-1764
19. Bonaccorsi L., Carloni V., Muratori M., et al. Androgen receptor expression in prostate carcinoma cells suppresses alpha6heta4integrin-mediated invasive phenotype. Endocrinology 141 (2000) 3172-3182
20. Zhang W., Razani B., Altschuler Y., et al. Caveolin-1 inhibits epidermal growth factor-stimulated lamellipod extension and cell migration in metastatic mammary adenocarcinoma cells (MTLn3). Transformation suppresor effects of adenovirus-mediated gene delivery of caveolin-1. J Biol Chem 275 (2000) 20717-20725
21. Bonaccorsi L., et al. Altered endocytosis of epidermal growth factor receptor in androgen receptor positive prostate cancer cell lines. J Mol Endocrinol 38 (2007) 51-66
22. Karlan B.Y., et al. Steroid hormone effects on the proliferation of human ovarian surface epithelium in vitro. Obstet Gynecol 173 (1995) 97-104
23. Vassilomanolakis M., Koumakis G., Barbounis V., et al. A phase II study of flutamide in ovarian cancer. Oncology 54 (1997) 199-202
24. Tumolo S, Rao BR, van der Burg ME et al. Phase II trial of flutamide in advanced ovarian cancer: an EORTC Gynaecological Cancer Cooperative Group Study. Eur J Cancer 19974; 30A: 911-914.